Tuesday, September 22, 2020 5:49:31 PM
A very rare situation here imo, we have:
1) Company rooted in biodefense (military and civilian)
2) Langer(MIT)/Edwards(Harvard) cofounders & DARPA History
3) Edwards launching a spinoff of new form of Hygiene in FEND which he co-created/co-studied back in 2010
4) Partnership moving forward in large ways with Johnson and Johnson tackling COPD/Lung Cancer & More...
5) Partnership moving forward in large ways with CIPLA tackling
ABPA in Pulmazole
6) New PUR3100 product announced treating Migraines
7) Nocion Therapeutics Pain Research Collaboration
8) Approved by the FDA (USA) & MHRA (U.K.)
9) Mass Liscensing opportunities within
**Any Covid Vaccine (Inhaled Version --> shift to Dry Powder)
**Any Covid Therapeutics (oral capsules to inhalation)
**Any Vaccine (Tuberculosis --> shift to dry powder)
**Any therapeutic on the market (Higher efficacy, lower dosage)
10) Wildcards (Buyout by JNJ, Spinoffs, Etc.)
Historic opportunity here if Pulmatrix and Partners can deliver.
$PULM
1) Company rooted in biodefense (military and civilian)
2) Langer(MIT)/Edwards(Harvard) cofounders & DARPA History
3) Edwards launching a spinoff of new form of Hygiene in FEND which he co-created/co-studied back in 2010
4) Partnership moving forward in large ways with Johnson and Johnson tackling COPD/Lung Cancer & More...
5) Partnership moving forward in large ways with CIPLA tackling
ABPA in Pulmazole
6) New PUR3100 product announced treating Migraines
7) Nocion Therapeutics Pain Research Collaboration
8) Approved by the FDA (USA) & MHRA (U.K.)
9) Mass Liscensing opportunities within
**Any Covid Vaccine (Inhaled Version --> shift to Dry Powder)
**Any Covid Therapeutics (oral capsules to inhalation)
**Any Vaccine (Tuberculosis --> shift to dry powder)
**Any therapeutic on the market (Higher efficacy, lower dosage)
10) Wildcards (Buyout by JNJ, Spinoffs, Etc.)
Historic opportunity here if Pulmatrix and Partners can deliver.
$PULM
All comments are solely my opinion. Please formulate your own opinion and act on your own accord on all actions you take.
Recent PULM News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 12:20:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 12:20:20 PM
- Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 04/22/2026 08:24:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 12:00:41 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 04/15/2026 08:15:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:16:05 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 03/26/2026 01:11:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 01:00:48 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 01:20:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:05:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2025 01:05:51 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/16/2025 12:21:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2025 12:05:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2025 12:20:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2025 12:05:31 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 06/16/2025 08:17:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/16/2025 08:15:38 PM
